APP and Cognitive impairment: Here, we demonstrate that a 4-week intranasal BMP9 treatment reduced both the amyloid plaque load and Aβ levels, inhibited tau hyperphosphorylation, suppressed neuroinflammation, and finally reversed the cognitive impairments in APPswe/PSEN1dE9 (APP/PS1) mice.